Biologic predictors of clinical improvement in rituximab-treated refractory myositis

Background To examine the longitudinal utility of a biomarker signature in conjunction with myositis autoantibodies (autoAbs) as predictors of disease improvement in refractory myositis patients treated with rituximab.